Regulatory eyes on Regeneron: US FDA issues CRL for Eylea

By Flora Southey contact

- Last updated on GMT

(Image: Getty/serdarcan)
(Image: Getty/serdarcan)

Related tags: Fda, Regeneron, Novartis

The US Food and Drug Administration has rejected Regeneron’s eye candidate, Eylea, but the biotech says it expects a final regulatory decision within two months.

According to Regeneron, “ongoing labelling discussions” ​prompted the US Food and Drug Administration’s (FDA’s) complete response letter (CRL) for Eylea (afibercept).

Eylea injection is a vascular endothelial growth factor inhibitor, designed for patients with wet age-related macular degeneration. “It is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels – vascular permeability – the eye,” ​the firm explained in a statement.

The firm expects FDA labelling discussions to close, and to “receive a final FDA action”​, within 60 days.

The regulatory setback comes just comes just months after Novartis instigated legal action against Regeneron​, claiming the biotech breached manufacturing intellectual property laws. According to Novartis, Eylea infringes on its Lucentis (ranibizumab) patents.

Regeneron firm did not respond to a request for comment ahead of publication.

Regeneron nests in with bluebird

Earlier this month, Renegeron announced a partnership​ with bluebird bio, to develop six cell therapy candidates. According to the terms, Regeneron will take a $100m (€86.2m) stake in bluebird bio common stock, with the firms sharing R&D costs for the six investigational therapies.

If the new drug applications are approved by the FDA, Regeneron have the option to co-develop and co-commercialise the drugs with bluebird bio.

Related topics: Markets & Regulations, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars